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Since the original description of the continuous replication of defective Friend spleen focus- 
forming virus (SFFV) x in mouse embryo fibroblasts (MEF) (1), nonproducer mouse and rat cell 
culture systems  have been developed for the purpose of estimating the coding capacity of the 
SFFV genome and to determine the relatedness of the SFFV genome to its associated Friend 
lymphatic leukemia-inducing  helper virus (LLV-F) and other murine leukemia viruses (MuLV) 
(2-4). Although it has been shown that the genome of fibroblastic cell grown SFFV contains 
two sets of distinguishable RNA sequences, one related to a portion of the LLV-F genome and 
one  related  to  murine xenotropic MuLV  (4), several  issues  obscure  the  meaning of these 
observations with respect  to the role of xenotropic-related sequences in the induction of Friend 
erythroleukemia. First, fibroblastic cells in culture are not a target for the expression of SFFV 
transformation markers and it has been assumed that the replication defective component of 
the Friend virus (FV) complex carries the oncogenic potential for the induction of classic Friend 
disease. However, to date there has been no direct evidence put forth demonstrating that SFFV, 
when purified free from standard MuLV helper and inoculated into a susceptible host,  is able 
to initiate a series of pathogenic events which ultimately lead to the induction and maintenance 
of an erythroleukemia. Also, the rapidity with which SFFV (as contained with LLV-F in the 
FV complex) is able to induce a  fatal erythroleukemia in both newborn and adult mice has 
limited attempts to unravel those pathogenic events which precede the development of leukemia 
and which might be characterized as preleukemia changes. This is in contrast to the LLV-F (5) 
and other MuLV model systems in which preleukemic syndromes have been defined (6, 7), and 
in which xenotropic MuLV expression has been correlated with the onset of leukemia (8). 
In a  previous study we have demonstrated that replication defective Friend SFFV 
particles can be physically separated from standard MuLV helper and that SFFV is 
able to persist  in vivo for a  3-d period  (9).  Here we present a  series of experiments 
which document the oncogenic potential of purified SFFV particles and define for 
the  first  time an extensive preleukemic phase  during which  SFFV  function(s) and 
host anti-leukemic reactivity may be investigated. 
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Materials and Methods 
Mice. Male and female 4- to 6-wk-old SIM (Fv-I "n) and SIM.R (Fv-lb~  mice are maintained 
in our breeding colony. These highly inbred mice (10) were originally obtained through the 
courtesy of Arthur A. Axelrad, UniversitbY  of Toronto, Canada. C57BL/6 (Fv-1 bb, Fv-2")  and 
BDFI i.e., (C57BL/6 ×  DBA/2)F1 (Fv-I n , Fv-Z ~) were obtained from The Jackson Laboratory, 
Bar Harbor, Maine. 
Viruses. All viruses used in this study were derived from in vitro (MEF) cultures. Exposure of 
NIH/3T3 cells to infectious FV complex has resulted in the productive infection of these cells 
by both defective Friend SFFV and NB-tropic LLV-F helper (1). Several preparations of FV 
complex have been subsequently derived from MEF-grown FV complex and provide homoge- 
nous stocks of FV complex for the studies presented here.  Virus from one particular clone of 
NIH/3T3 cells  was  used throughout the study. This virus has an LLV-F to SFFV ratio of 
approximately 3:1. 
Isolation and maintenance  of LLV-F (11) and Gross leukemic virus (GLV)  (12, 13) has been 
previously described. In all instances, the helper virus used to reveal the presence of SFFV in 
gradient samples and used for in vivo rescue of SFFV consisted of homogenous stocks of either 
LLV-F or GLV each having an NB-tropic host  range and titers of greater than 5  ×  105 FIU 
per ml. All in vitro rescues  of SFFV were  done using LLV-F derived from NIH/3T3 cells 
chronically infected with cloned LLV-F. 
All virus stocks  used  in these  experiments were  free  of detectable xenotropic virus since 
sedimentable RNA-dependent DNA polymerase activity could not be detected  in 200-fold 
concentrated culture fluids of MvlLu (CCL64~ mink cells 30 d  after exposure of cultures to 
each of the viruses in question. Finally, the method of purifying SFFV free from LLV-F helper 
has  been  described  in  detail  (9). Briefly,  cloned  FV  harvested  from  NIH/3T3  cells  was 
disaggregated by using ultrasonic shock  (1  pulse per s for 8 s using a  Branson sonifier and 
microtip model W-200P) and layered onto a preformed 0-20% sucrose sedimentation gradient. 
After centrifugation (SW27  rotor for  30 rain at  20,000  rpm at  4°C), the tube was  bottom- 
punctured and 1.0-ml samples each were collected.  Those samples seen to contain only SFFV 
(see  spleen  focus  assay  below)  were  layered  onto  preformed  20-40%  sucrose  equilibrium 
gradients and centrifuged for 24 h at 4°C (SW27  rotor at 26,500 rpm). Samples were again 
taken by, bottom-puncture and those shown to contain pure SFFV (density ~- 1.14 g/ml) were 
pooled and used in the studies presented below. 
Cultured Cells and Maintenance  Medium.  Swiss mouse 3T3FL cell lines were originally  obtained 
from Dr. R. H. Bassin (National Cancer Institute, Bethesda, Md.). The origin of these 3T3FL 
cells has been described as has the origin of the murine sarcoma virus-transformed cells termed 
sarcoma-positive leukemia-negative (S + L-) mouse cells (14). 3T3FL cells, and their S+ L- 
counterparts (clone C-243-3)  are maintained by routine trypsinization every 3-4 d. Culture 
medium consists of McCoy's 5A (Grand Island Biological Co., Grand Island, N. Y.) containing 
10% heat-inactivated fetal calf serum. 
NIH/3T3 cells were obtained from P. Besmer, Center for Cancer Research, MIT, Cambridge, 
Mass.  This cell  line is passaged  by trypsinization before confluence in Dulbecco's modified 
medium (DMEM, Grand Island Biological Co.) supplemented with antibiotics and 10% heat- 
inactivated calf serum. 
Clone III6A of feral  mouse embryo fibroblasts (SC-1 cells)  (15) was kindly provided by P. 
Besmer,  as  was the mink cell  line MvlLu (CCL64)  (16). These cell  lines are maintained in 
DMEM with 10% heat-inactivated fetal calf serum and antibiotics and are passaged every 4-5 
d before forming a confluent monolayer. 
All virus-producing  cell clones were derived from cells infected with an initial multiplicity  of 
infection (moi) of not greater than 0.02. SC- I/LLV-F cells are maintained  in a manner identical 
to the parental SC- 1 cell line and chronically produce LLV-F with a titer of approximately 5 
×  105 infectious units per ml of unconcentrated culture medium. In addition, NIH/3T3 cells 
chronically infected with  cloned  LLV-F  (clone  NIH/LLVB6)  are  maintained in  DMEM 
supplemented with 10% heat-inactivated calf serum and are subcultured every 4-5 d as above. 
This cell  line was  used preferentially for all in vitro rescues  of SFFV from SIM spleen cells 
since, in that way, both spleen cell and fibroblast were of Swiss origin. 
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the spleens  with  DMEM  until  the  majority of the spleen  cells had  been  removed  from  the 
spleen stroma. The cells were then passed through a  wire mesh (110/in),  nucleated cells were 
counted using a  Coulter counter  (ZBI), the percent viability was determined  via trypan  blue 
dye exclusion (usually --90%), and cells were adjusted to the desired concentration in DMEM 
with fetal calf serum. The cells were kept in tubes in ice water until used. 
Virus Detection Assays 
SPLEEN FOCUS ASSAY.  All SFFV preparations as well as culture media and sucrose gradient 
samples  suspected  to  contain  SFFV  were  titrated  in  vivo with  the  spleen  focus  assay  (17). 
Samples of SFFV diluted into phosphate-buffered saline (PBS) alone, or diluted into PBS with 
exogenous LLV-F added  (10  a FIU) were injected i.v. into susceptible mice, seven per group. 9 
d  later,  their spleens were removed and fixed in Bouin's solution.  Discrete foci on the splenic 
surface  were  counted  macroscopically,  and  virus  titers  (mean  number  of foci per spleen  X 
dilution  factor)  are expressed in focus-forming units  (FFU) per ml where one FFU represents 
that  amount  of virus required  to induce  an  average of one focus per spleen.  All LLV stocks 
were free of detectable SFFV. 
S 4" L-  INFECTIOUS CENTER ASSAY FOR DETECTION OF MOLV HELPER ACTIVITY.  The number of 
S + L-  cells producing  rescued  MSV after exposure to NB-tropic MuLV  helper only or FV 
complex (SFFV plus  LLV-F helper)  are measured  by using an infectious center assay which 
has been described in detail previously (9). Briefly, 0.5 ml of each serial dilution of LLV-F only 
or SFFV and LLV-F is inoculated into  105 S + L-  cells pretreated  with DEAE-dextran. After 
an  adsorption  period  of  1 h,  5  ml  fresh  medium  containing  10%  heat-inactivated  fetal calf 
serum is added to each dish. 8-16 h  postinfection,  104 cells are transferred into recipient plates 
already containing 105 normal 3T3FL cells. Transferred cells releasing infectious MSV give rise 
to large foci of recruited transformed  3T3FL cells which are easily enumerated 3-4 d  after cell 
transfer.  Virus  titers  (mean  number  of foci  per  dish  multiplied  by  the  dilution  factor)  are 
expressed in FIU per ml where one FIU represents that  amount of virus required to induce an 
average of one focus per dish. 
The  S+ L-  focus assay  is used  for detecting and  quantifying MuLV  in  the presence and 
absence of SFFV because SFFV neither provides a helper function to rescue MSV from S + L- 
cells nor interferes with LLV-F rescue function(s) in this assay (9). In addition, 3T3FL cells and 
S + L-  cells are highly sensitive to MuLV helper infection and do not express Fv-1 restriction 
(18).  For all these reasons, this infectious center assay is the ideal method for the detection and 
quantification of ecotropic MuLV helpers. 
AssAY  FOR  VIRION-ASSOCIATED REVERSE  TRANSCRIPTASE.  Any  fluids  to  be  tested  for  RNA- 
dependent  DNA polymerase activity were harvested and clarified by centrifugation at  10,000 
rpm for 15 min. These fluids were then concentrated 200-fold via centrifugation at 39,000 rpm 
for 90  rain  and  pellets were resuspended  in 0.01  M  Tris-HC1,  pH  7.8.  Reverse transcriptase 
reaction  mixtures  were  incubated  and  quantified  according  to  the  technique  of Fan  and 
Baltimore (19). 
In  Vivo Rescue Technique,  Animals were inoculated with  10  a FFU of equilibrium gradient- 
purified SFFV.  At the intervals indicated  in Fig.  1,  groups of these animals were inoculated 
with excess LLV-F in an attempt  to reveal SFFV persistence. These animals were sacrificed 9 
d after LLV-F inoculation, their spleens were removed, fixed in Bouin's solution, and observed 
for the presence of rescued  SFFV-induced spleen  foci. Since only a  spleen cell infected with 
both SFFV and an MuLV helper produces SFFV progeny resulting in the rapid enlargement 
of a  focus by spread  of SFFV infection, this in vivo rescue technique is a  valid approach  for 
detecting latent SFFV infection (20). 
In  Vitro SFFV Rescue Technique.  Animals  suspected  to  be  harboring  latent  SFFV  were 
hemisplenectomized,  and  the  spleen  fragments  were  prepared  as  a  single cell suspension  as 
described  above.  107  nucleated  cells were  pipetted  into a  60-mm  Falcon  tissue  culture  dish 
already containing a mixture of normal and LLV-F-producing NIH/3T3 cells. The spleen cells 
were allowed to settle onto the monolayer and remained there undisturbed  for 4-5 d. At that 
time, the culture  fluids containing the spleen cells were harvested, clarified of all particulate 
matter by centrifugation at  10,000 rpm for 30 min, and assayed for the presence of SFFV and 
LLV-F by using the methods  already  described.  The  NIH/LLV  cells onto which the spleen 
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culture fluids from the subcultures were also harvested and assayed for the presence of infectious 
SFFV and LLV-F. 
Animal Irradiation and Spleen Cell Transplantation.  Recipient mice were exposed to 800 rads of 
total-body irradiation  in a  small animal irradiator with two 137Cs sources (Gamma Cell 400, 
Atomic Energy of Canada, Ltd., Toronto). Each mouse was infused i.v. with usually 2  ×  106 
spleen cells from normal Swiss, SFFV + preleukemic, or FV leukemic mice in a 0.5-ml vol within 
2  h  of irradiation.  7  d  postcell  transplantation,  proliferation  of the  donor-derived  cells  in 
the spleens of recipient mice was assessed  by measuring the incorporation of 5-iodo-2'-deoxyuri- 
dine-125I  (IUdR),  a  specific  DNA  precursor  and  thymidine  analogue.  The  mice  were  each 
injected with  10 -7 M  5-fluoro-2'-deoxyuridine (FUdR)  i.p.  in a  0.1-ml vol  1 h  before the i.p. 
injection  of 0.5  /~Ci IUdR.  FUdR  inhibits  endogenous  thymidylate  synthesis  and  enhances 
IUdR uptake under these conditions. Spleens were removed 24 h after isotope injection and the 
12sI radioactivity was measured in a crystal scintillation counter (Packard Instrument Co., Inc.,. 
Downers Grove, Ill.).  In addition,  the spleens were fixed in  Bouin's solution  to facilitate the 
enumeration of donor spleen cell growth in the form of spleen colonies. 
Spleen Colony Assay  for SFFV-Induced Tumor Cells (TCFU).  Since the cell-free fluids derived 
from spleen cell preparations were free of detectable SFFV and ecotropic MuLV activities by 
using the assay techniques described above, and since the SFFV + erythroleukemic cells obtained 
in this study were transplantable in unirradiated mice, we were able to detect and quantify the 
numbers of SFFV-induced tumor cells in various spleen cell preparations on the basis of spleen 
colony formation in syngeneic SIM.R mice (20). 
Results 
Duration  of Persistence of Rescuable Friend  SFFV in  Swiss  Mice.  We  have  recently 
demonstrated  that defective Friend  SFFV particles differ significantly from standard 
MuLV  helpers with respect to their sedimentation  properties and buoyant density in 
sucrose  (9).  Exploitation  of these  expressed  differences  in  virion  physical  properties 
has  made  possible  the  purification  of infectious  SFFV  particles  free from  standard 
helper  virus.  It  has  also  been  shown  that  SFFV  can  be separated  from  replicating 
MuLV  helper  by using cell  culture  techniques.  Rescuable  SFFV  can  persist  in  the 
absence of replicating  helper for long periods of time in vitro in both NIH/3T3  and 
BALB/c nonproducer  cells (2, 3). 
In  a  series  of  preliminary  experiments  designed  to  investigate  the  infectivity 
properties of purified SFFV for hemopoietic target cells, we have observed that SFFV 
is able to persist in vivo for a  3-d period  (9). This observation,  together with the cell 
culture studies mentioned above, suggested to us that purified SFFV might be able to 
persist  in  vivo  (i.e.,  in  stem  cells  of a  renewing  hemopoietic  cell  population)  for an 
extended  period.  To determine  if a  target  cell for SFFV  persistence is a  hemopoietic 
stem cell or a  differentiating cell population  which would eventually come to the end 
of its  life  cycle  and  of necessity  eliminate  nonreplicating  SFFV  from  the  host,  we 
inoculated  4-wk-old female SIM.R mice i.v. with  gradient  purified  SFFV.  Of the 40 
animals inoculated,  4 were coinfected with  104 FIU of LLV-F helper to determine the 
focus-forming  efficiency  of our  purified  SFFV  stock.  9  d  after  LLV-F  inoculation, 
these  four mice were sacrificed  and  their spleens were removed and  fixed in Bouin's 
solution.  The average number of SFFV-induced  loci appearing on the surface of the 
fixed spleens was >100  (range of >100  to confluent)  (Fig.  1, day 0).  Four additional 
mice that had received only SFFV were also sacrificed. In all instances,  their spleens, 
livers,  and  other  lymphoid  organs  were  free  of macroscopic  and  microscopically 
detectable  disease.  We  thus  concluded  that  the  entire  group  of SIM.R  mice  had 
initially  received approximately  500-10 a FFU of infectious  SFFV particles  and  that 
the remainder of the group could be used to study SFFV persistence and pathogenicity. 344  PERSISTENT SPLEEN  FOCUS-FORMING VIRUS INFECTION IN MICE 
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FIG.  1.  Kinetics of rescue of defective Friend SFFV from the spleens of persistently infected SIM.R 
mice. On day 0, 40 mice were each inoculated with approximately  103 FFU of SFFV. At the time 
intervals indicated,  groups of four mice each were inoculated  with  104 FIU of NB tropic LLV-F 
helper.  SFFV  rescue and  subsequent  development  of spleen foci of erythroleukemic  cells was 
monitored on day 9 posthelper inoculation  (0). Beyond day 36 post SFFV administration,  only in 
vitro rescue techniques were employed. Hemisplenectomies were performed and histological spleen 
preparations were viewed for the presence of malignant change. The remaining tissue was prepared 
as a single cell suspension and exposed to helper virus in culture as follows: m, spleen cells cultured 
alone; F], spleen cells cocuhured  with NIH/3T3 cells chronically infected with NB-tropic LLV-F; 
F-l, spleen cells cocuhured with NIH/3T3 cells chronically infected with NB-tropic GLV. 
We subsequently  inoculated  groups of four SFFV-pretreated  mice with LLV-F helper 
on  the  days  indicated.  These  animals  were  monitored  for in  vivo SFFV  rescue  by 
using the spleen focus assay since SFFV defectiveness for focus formation in vivo is a 
reflection of SFFV  dependence  upon its associated helper virus for rapid synthesis of 
infectious  SFFV  progeny and  resultant  spread  of SFFV  infection  (20).  As shown  in 
Fig.  1, a  consistent  reduction  in the numbers of rescued spleen foci was observed as a 
function of time between SFFV and LLV-F inoculations,  Beyond 24 d, no spleen foci 
were observed. Further, we examined peripheral blood smears and histological spleen 
preparations  obtained from SFFV-pretreated  mice inoculated with LLV-F on day 32 
and  day 36, but could find no evidence of SFFV- or LLV-induced  leukemic change. 
These  data  suggested  to  us  that  SFFV  had  been  excluded  from  the  hemopoietic 
system of these mice as the cells originally infected by SFFV differentiated.  However, 
it  was  also  possible  that  these  mice  had  either  become  immune  to  LLV-F  via  the 
expression of cross-reacting  SFFV-encoded  antigen(s)  (i.e., gag gene products  [3])  or 
had restricted the expression of LLV-F via SFFV defective-interfering  (DI) properties 
(9).  Since  individual  serum  samples  prepared  from  these  mice  were  not  able  to 
neutralize or otherwise interfere with SFFV or LLV-F infection  (data not shown), we 
presumed SFFV-DI activity and continued  to probe for evidence of SFFV persistence 
using in vitro rescue techniques  (Materials and Methods).  Four mice which had been 
inoculated  64  d  previously  with  purified  SFFV  were  anesthetized  and  one  half of 
each  spleen  was removed.  A  section  from each  spleen  was viewed  histologically  for 
evidence of leukemia and  found  to be free of detectable  Friend  disease  (Fig.  2). The 
remainder of each spleen was pooled, prepared as a washed single cell suspension, and 
10 ?  nucleated  cells  were  cultured  in  the  presence  of NIH/3T3  cells  productively 
infected  with  NB-tropic  LLV-F  helper  (NIH/LLV  cells).  The  original  spleen  cell ROBERT J.  ECKNER  AND  KRISTINE L.  HETTRICK  345 
FtG.  2.  Histological preparation  of an  adult  SIM.R  spleen. This  animal  received 10  a FFU of 
purified defective Friend SFFV in the absence of detectable MuLV helper 64 d before splenectomy. 
A low power view of the spleen demonstrates the preservation of normal architecture. Note the 
prominent germinal center in the white pulp with the central arteriole (single arrow), the distinct 
marginal zone (double arrows), and red pulp (hematoxylin and eosin X 60). 
wash as well as cell-free supernatant  fluids from 4 and 5 d  cocultures did not contain 
detectable  SFFV.  However, fluids harvested from 3-wk cultures contained >10  s FFU 
of Friend  SFFV  (Fig.  1)  and  an  excess  of LLV-F helper.  Since  the  fluids  from the 
original  spleen  cell  suspension  contained  no  detectable  virion-associated  RNA-de- 
pendent  DNA  polymerase  activity,  and  since  fluids  from  4  and  5  d  cocuhures 
contained only LLV-F activities,  we presumed  that  an extremely limited  amount of 
SFFV was initially rescued from the dying spleen  cell preparation.  Further,  rescued 
SFFV together with LLV-F helper most likely coinfected the normal NIH/3T3  cells 
provided  in  the  culture  mixture  (Materials  and  Methods)  giving  rise  to  chronic 
production  of this  FV  complex.  This  same  in  vitro  SFFV  rescue  technique  was 
employed using four mice which had  been inoculated  96 d  previously with  purified 
SFFV.  Again, there  was no histological evidence of leukemia  detected  in  the donor 
spleens and  SFFV was rescued and observed at  3 wk by using NIH/LLV  cocuhures 
(Fig.  1).  To  determine  if SFFV  could  be  rescued  from  these  persistently  infected 
spleen  cells  (SFFV  +  cells)  more  effectively  by  a  helper  virus  not  included  in  the 
Friend-Moloney-Rauscher  (FMR)  group,  we cultured  107 SFFV  ÷ spleen  cells in the 
presence of NIH/3T3 cells productively infected with NB-tropic Gross leukemia virus 
(NIH/GLV cells). The amount of infectious helper virus released from our NIH/LLV 
and  NIH/GLV  cultures  were  virtually  identical  based  upon  virus  yield  per  cell. 
However, GLV was not as effective in rescuing SFFV in this culture system  (Fig.  1). 
A  similar result was obtained by Fieldsteel et al.  (21) who attempted to rescue SFFV 
from  FV-induced  reticulum  cell  sarcomas  using  GLV helper.  Although  we  do  not 
know the  reason  for this  reduction  in  expressed  GLV helper  function(s),  it  may be 
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properties.  Finally, both SFFV(LLV-F)  and  SFFV(GLV)  pseudotypes were able to 
induce a  pattern of Friend disease identical to that induced by the strain of in vitro 
(MEF)-maintained  FV complex from which the SFFV was originally purified. This 
disease  pattern  included  the  induction  of polycythemia  (hematocrits  _>70%) in  all 
infected mice. 
Oncogenic Potential  of Purified Friend SFFV Particles.  Although  we  have not  deter- 
mined the type or the frequency of the persistently infected SFFV + spleen cell, it is 
clear from the data presented above that the target cell for SFFV persistence is either 
a very long-lived cell or a self-renewing cell, or both. Since SFFV particles are able to 
establish a  latent  form of persistent  virus infection for a  period of at least 90 d, we 
embarked upon a series of experiments to determine if SFFV particles alone carry the 
erythroleukemia-inducing potential traditionally expressed by the FV complex (i.e., 
SFFV in the presence of LLV-F). Although no histological evidence of Friend disease 
could be detected in SFFV + mice 96 d after virus inoculation, the possibility remained 
that  mice  harboring  rescuable  SFFV  also  harbored  hemopoietic  cells  expressing 
preleukemic  change  or  expressing  SFFV  transformation  markers  (i.e.,  persistently 
infected mice might contain small numbers of transplantable Friend tumor cells). It 
is reasonable to assume that at least in part host immune mechanisms are responsible 
for the disease-free status of these animals. The absence of disease could be explained 
by either active suppression of the SFFV + transformed phenotype on the part of the 
persistently infected  mice, or by an effective killer cell  mechanism directed  against 
these cells. Therefore, we elected to conduct  cell transplantation  experiments using 
syngeneic mice <-5 days of age in an attempt to circumvent possible immune functions 
which  might be operative in  mature adult  animals and  able to restrict  the  growth 
and resultant detection of SFFV + transformed cells. We inoculated a cell suspension 
freshly  prepared  from  a  spleen  fragment  obtained  via  hemisplenectomy  from  an 
SFFV ÷ SIM.R mouse  (96 d  post  SFFV).  Each  of 25  5-d-old recipient  SIM.R mice 
received  an  i.p.  injection  of  107  cells.  Within  a  20-d  period,  the  recipients  of this 
attempted spleen cell transplant were observed to have enlarged and palpable spleens. 
Peripheral  blood smear preparations were found  to contain  benzidine-positive, nu- 
cleated  erythrocytes,  large  mononuclear  cells,  and  a  preponderance  of extremely 
fragile smudged cells. Overall, the pattern of disease was identical to that originally 
described by Friend  (22), and the histopathology of the disease induced is presented 
in Fig. 3 and 4. The clusters of leukemic cells seen within the hepatic sinusoids are at 
various stages of erythroid  differentiation  (Fig.  4).  The average leukocyte count  at 
day 20 postceli inoculation was 95,000/mm 3, and hematocrit values ranged from 27 
to 32% (normal values for SIM.R are approximately 40%). We now have established 
an in vivo maintained tumor cell line from these leukemic animals and preliminary 
studies  concerning  the  donor  origin  of  this  leukemia  are  presented  below.  The 
remaining  SIM.R  mice which  had  been hemisplenectomized and  shown  to harbor 
Friend  SFFV  (Fig.  1)  began  to  die  of typical  Friend  disease  134  d  after  SFFV 
inoculation. The disease observed in these SFFV-infected mice was identical to that 
described above. It is interesting to note that, although the SFFV used in this study 
was purified from a cloned stock of in vitro (MEF)-maintained FV complex which is 
a  polycythemia-inducing  strain  (23),  and  although  rescued  SFFV-LLV  complex 
induced a polycythemia, all leukemic mice inoculated only with SFFV were severely 
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Fro.  3.  Histopathology of leukemia induced within a  20-d period in an infant SIM.R who had 
received spleen cells prepared from an SFFV  + yet histologically normal spleen cell donor. The large 
leukemia cells flood the splenic pulp and virtually replace the smaller lymphocytes 0aematoxylin 
and eosin,  X  60). 
concentrated supernatent fluids from either liver or spleen cell suspensions prepared 
from  leukemic  mice  using  an  assay  for  the  detection  of virion-associated  reverse 
transcriptase activity and an S + L-helper assay for ecotropic MuLV. 
Rejection of SFFI~ Preleukemic Spleen Cells by Nonimmunized Lethally Irradiated Syngeneic 
Recipient Mice.  A  clear demonstration of the erythroleukemia-inducing potential of 
purified Friend SFFV particles allows us to define the SFFV latency period up to at 
least 90 d postinfection as a preleukemic phase. With the knowledge that preleukemia 
in  other MuLV systems may be associated with changes  in  the expression of viral 
(e.g., xenotropic MuLV gp70) and host (e.g.,  H-2 and Thy 1.2) cell surface antigens 
(6,  8,  24)  and  with  the  knowledge  that  FV-infected  mice  (25)  and  in  vitro  bone 
marrow cell cultures (26) either contain increased numbers or sustained proliferation 
ofpluripotent hemopoietic stem cells (CFU-S), we were desirous to know if the spleen 
cells obtained  from SFFV  ÷ mice expressed any detectable alteration  in  membrane 
surface markers. We elected to conduct cell transplantation studies because this would 
allow us to enumerate the frequency of  CFU-S per SFFV  + spleen, the transplantability 
of such cells, and  their ability to protect lethally irradiated mice from hemopoietic 
death.  Recipient  SIM  and  SIM.R  mice  were  exposed  to  800  rads  of total-body 
irradiation and infused intravenously with one of several different spleen cell prepa- 
rations listed in Table I. The proliferation of donor cells in  the spleens of recipient 
mice was estimated by measuring the incorporation of 125IUdR and by enumerating 
the  numbers  of macroscopically  detectable  surface  spleen  colonies  8  d  after  cell 
inoculation. As shown in Table I, exp. 1, normal SIM.R donor spleen cells proliferated 
effectively in  both  SIM.R  (Fv-1  bb)  and  SIM  (Fv-I  nn)  adults.  We were thus  able to 348  PERSISTENT SPLEEN  FOCUS-FORMING VIRUS INFECTION  IN  MICE 
Fie.  4.  A  high  power  view  of the  liver of the  same  leukemic  animal  presented  in  Fig.  3  to 
demonstrate the infiltrate of large leukemic cells with large vesicular nuclei and prominent nucleoli. 
The clusters of leukemic cells within the hepatic sinusoids are seen as foci of normoblasts  and more 
primitive erythroid cells at various stages of differentiation. 
utilize  both  strains  of Swiss  mice  as  recipients  of spleen  cell  grafts  obtained  from 
SIM.R  donor mice inoculated 64 d  previously and shown to contain rescuable Friend 
SFFV.  The  results  of this  attempted  cell  transplant  (Table  I,  exp.  2)  indicate  that 
these  preleukemic  cells were  not  able  to  proliferate  significantly  in  SIM  or  SIM.R ROBERT J.  ECKNER  AND  KRISTINE L.  HETTRICK  349 
TABLE  I 
Proliferation of Normal, SFFV + Preleukemic, and FV Complex (SFFV-LL V)-Induced Leukemic Spleen 
Cells in Irradiated Syngeneic Recipient Mice 
Mean no. of 
Donor SIM.R (cells grafted)  Recipient strain  Mean splenic incorpora- 
(no. of mice)  tion of 125IUdR*  spleen colo- 
nies (CFU-S)$ 
cpm  % uptake 
Exp.  1 
Normal (2 ×  10  s) 
None 
None 
Exp. 2 
Preleukemic:  inoculated 
SFFV +64 d§ (10  s) 
with 
SIM.R  (10)  7,860  (1.0)  54 
SIM  (10)  6,840  (0.86)  44 
SIM.R  (5)  390  (0.05)  0 
SIM  (5)  560  (0.07)  0 
SIM.R  (5)  720  (0.08)  0 
SIM  (3)  270  (0.03)  0 
SIM  (4) 
(Isotope 
jected) ll 
not  in- 
Exp. 3 
Normal (2 x  10  e')  SIM.R  (6)  8,220  (0.98)  40 
Leukemic:  inoculated  with  10  z  SIM.R  (6)  4,860  (0.58)  38 
FFU of FV complex  + 7 days 
(10 ~) 
None  SIM.R  (5)  830  (0.03)  1.6 
*  IUdR-labeled with radioactive  125I was used to assess DNA synthesis in the spleens of irradiated mice 
engrafted with spleen cells (Materials and Methods). All recipient mice were exposed to 800 rads of total- 
body irradiation and proliferation was estimated 8 d after irradiation and spleen cell transplantation. 
Standard errors  for mean splenic  isotope  uptake were  ~10%  and the overall  survival  of the animals 
assigned to this series of experiments was 90%. 
:]: The recipients' spleens were  removed  8 d  after irradiation and cell transplantation, fixed in Bouin's 
solution, and viewed macroscopically  for the presence of surface colonies. 
§ This cell suspension was prepared from the spleens of histologically normal (Fig. 2) donor mice which 
had received an inoculum of-~ 103 FFU of purified defective SFFV 64 d previously. These cells contained 
rescuable SFFV as shown in Fig. 1. 
II These animals did not receive isotope and were not sacrificed, but monitored for potential hemopoietic 
repopulation and/or tumor development after i.v. injection of SFFV  + spleen cells. All four mice died of 
hematopoietic failure 22-28 d after irradiation. 
recipients. Four additional SIM mice were not injected with isotope but instead were 
monitored for potential hemopoietic repopulation and CFU-S development. All four 
mice  died  of hemopoietic  failure  22-28  d  after  irradiation and  cell  transplantation 
indicating that  the SFFV  ÷ donor spleen cells did not contain transplantable CFU-S 
and could not protect these animals from hemopoietic death. In contrast, spleen cells 
prepared  from  FV-leukemic  SIM.R  donors  grew  effectively  in  irradiated  SIM.R 
recipients,  and  gave  rise  to  the  expected  number  of spleen colonies.  The  failure of 
SFFV +  spleen ceils  to  proliferate  in  syngeneic  recipient  mice  was  not  due  to  the 
diminished viability of these  donor cells since the number  of cells transplanted was 
standardized  to  100%  viability based upon  trypan blue dye exclusion test.  Further, 
this  SFFV +  spleen cell  preparation  proliferated  normally  (A  blastogenesis  2  ×  104 
cpm)  in vitro in response to B- and T-cell mitogens. 
From the data presented, it appeared that a radio-resistent host-versus-graft reaction 
was operative in these nonimmunized  mice and directed only against SFFV  ÷ preleu- 
kemic cells. Rossi et. al. (27, 28) have previously investigated the proliferative capacity 350  PERSISTENT SPLEEN  FOCUS-FORMING VIRUS INFECTION IN  MICE 
TABLZ II 
Effect of Silica  Particles upon the Proliferation of SFFV + Preleukemic Spleen Cells in Irradiated Syngeneic 
Recipient  Mice* 
Donor ceils (2 X  106 en-  Recipient SIM.R  Mean splenic incorpora-  Mean no. of spleen colo- 
grafted per animal)  ± silica treatment  tion of lS~IUdR~  nies (CFU-S)§ 
cpm  ~  uptake 
Normal SIM.R  -(6 mice)  10,700  (1.25) 
+ (3 mice)  10,900  (1.28) 
Preleukemic:  SIM.R inocu-  -(6 mice)  230  (0.03) 
lated with SFFV  +96 dll 
None 
Individual mice 
+  6,630  (0.78) 
+  7,930  (0.93) 
+  3,220  (0.38) 
+  1,010  (0.12) 
+  1,190  (0.14) 
+  3,220  (0.38) 
+  270  (0.03) 
+  740  (0.09) 
+  630  (0.07) 
+  720  (0.08) 
+  820  (0.09) 
+ (6 mice)  260  (0.03) 
52 
57 
6  NN  ~]'N,  (P < 0.02) 
34 
16  eptible 
5  14j 
16 
1  Resistant 
0.31 
* Mice receiving silica particles were injected i.v. with 2.5 mg of sonicated silica 24 h before irradiation and 
cell transplantation. 
:~ IUdR-labeled with radioactive  ~2~I was used to assess DNA synthesis in the spleens of irradiated mice 
engrafted with spleen cells (Materials and Methods). All recipient mice were exposed to 800 rads of total- 
body irradiation and proliferation  was estimated 8 d after  irradiation and spleen cell transplantation. 
Standard errors for mean splenic isotope uptake for each group (excluding values given for individual 
mice) were  15-20% and the overall survival  of the animals assigned to this series of experiments was 
80%. 
§ The recipients' spleens were removed  8 d  after irradiation and cell transplantation, fixed in Bouin's 
solution, and viewed macroscopically for the presence of surface colonies. 
I1 This cell  suspension  was  prepared  from  the spleens of histologically  normal donor mice which had 
received  an inoculum of 103 FFU of purified  defective  SFFV 96 d  previously. These  cells contained 
rescuable SFFV as shown in Fig. 1. 
of FV-infected marrow cells in syngeneic, allogeneic, and hybrid mice. They concluded 
that within 3 h  after FV infection, the enhanced expression of hemopoietic histocom- 
patibility gene(s) (Hh) resulted in deficient growth ofFV +  cells in irradiated recipient 
mice. Since this early signal of FV-induced infection and perhaps transformation may 
be analogous to the SFFV ÷ preleukemic phase described here, we set out to determine 
if measures known to abrogate or prevent the rejection of hemopoietic allografts by 
lethally  irradiated  mice  might  also  facilitate  the  growth  of SFFV  +  spleen  cells  in 
syngeneic mice.  Groups  of SIM.R  mice were  injected intravenously with  2.5  mg of 
sonicated  silica  particles  24  h  before  irradiation  and  spleen  cell  transplantation. 
Pretreatment  of mice with  this  anti-macrophage  agent  suppresses  both  hybrid and 
allogeneic resistance  to  hemopoietic  cell  grafts  (29).  As  shown  in  Table  II,  normal 
SIM.R  donor  spleen  cells  proliferated  equally  well  in  silica  and  nonsilica treated 
SIM.R  recipients.  We  were  also  able  to  repeat  the  observation  that  preleukemic 
SFFV +  spleen cells fail to  grow  in syngeneic recipient mice.  In this experiment,  all 
SFFV ÷ cells were obtained from SIM.R mice inoculated 96 d  previously with purified ROBERT  J.  ECKNER  AND  KRISTINE  L.  HETTRICK 
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Autonomous Growth and Transplantability of Hemopoittic Cells Harboring Rescuable SFFV 
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Mean no. of 
Source of donor cells (no.  Recipient strains (pre-  Mean splenic incorpo-  spleen colonies 
grafted)  treatment)  ration of 12SlUdR*  (CFU-S) 
cpm  % uptake 
Exp.  1 
Enlarged  spleens  from  SIM.R (800 rads only)  11,900  (1.13)  30 
SIM.R  inoculated  at  SIM.R (800 rads +  silica)  9,950  (0.95)  41 
birth  with  10  r  SFFV  +  BDF1  (800 rads only)  360  (0.03)  0 
preleukemic  spleen  cells 
(2  X  10~* 
Exp. 2 
Same as above (5  ×  107) 
Primary recipients (inter-  Secondary adult recip-  Mean no. of 
ients (no. of cells  spleen colonies 
val)§  grafted)  (TCFU)[[ 
Infant SIM.R (10 d)  SIM.R  (105)  >100 
BDF1  (105)  10  (blotchy) 
Infant BDF~  (10 d)  SIM.R  (10 ~)  >100 
(to')  a9 
BDFI  (10  s  )  6.2 
(lO')  o 
* IUdR-labeled with radioactive 12hi was used to assess DNA synthesis in the spleens of irradiated mice 
engrafted with spleen cells (Materials and Methods). All recipient mice were exposed to 800 rads of total- 
body irradiation and proliferation was estimated 8 d  after irradiation and spleen cell transplantation. 
Standard errors for mean splenic isotope uptake were 15% and the overall survival of the animals assigned 
to this series of experiments was 75%. 
:]: This cell suspension was prepared from the spleens of leukemic SIM.R mice (confirmed histologically  7 
and t/resented in  Figs. 3  and 4)  which 20 d  earlier as infants had received an  i.p. inoculation of 10 
histologically normal (Fig. 2) SFFV  + preleukemic spleen cells. This transplant was conducted using cells 
harboring rescuable SFFV (Fig.  1,  +  96 days). 
§ 5-day-old SIM.R or BDFI mice were inoculated i.p. with SFFV  + spleen cells since infant mice <21 d old 
are not able to reject foreign hemopoietic cell grafts. 10 d after inoculation, these mice were sacrificed and 
their spleens were used as a source of cells for the second transplant. 
[[ 6- to 8-wk old adult  secondary recipient  mice were inoculated  i.v.  in  an  attempt  to monitor for the 
presence of transplantable TCFU of SIM.R or BDFI origin. 
SFFV particles. In contrast to this lack of cell growth (IUdR uptake not greater than 
that of radiation controls) approximately 50% of the silica-pretreated recipient mice 
permitted extensive growth of SFFV  + cells. Although there was a variable silica effect, 
this is not unexpected (29) and there was a significant difference (P <  0.05) between 
the susceptible and  resistant  groupings of silica-treated mice. The cell proliferation 
and spleen colony formation observed in these mice did not result from the stimulation 
of endogenous spleen colonies (data not shown) since infusion of sonically disrupted 
cells  into  lethally irradiated  and  silica  pretreated  mice  gave negative  results.  The 
observation that a single intravenous injection of silica particles greatly reduced the 
ability of irradiated mice to resist syngeneic SFFV  + spleen cell grafts suggests that a 
radioresistant  effector cell  mechanism  which  has  been  characterized  as  marrow- 
dependent  and  free of T- and  B-cell  influences  (30,  31)  may be  operative  in  the 
suppression or elimination of SFFV  + preleukemic cells. 
Transplantability and Donor Origin of an SFFV-Induced Leukemia.  The 5-d-old SIM.R 
mice that received an intraperitoneal injection of 107 preleukemic SFFV  + (plus 96 d) 
spleen cells developed palpable spleens within 20 d. Since SFFV and ecotropic MuLV 352  PERSISTENT  SPLEEN FOCUS-FORMING VIRUS INFECTION IN MICE 
activities could not be detected in the cell-free fluids from either donor or recipient 
spleen cell suspensions, we presumed initially that the rapidly expanding population 
of leukemic cells was of donor origin. The availability of large amounts of leukemic 
spleen tissue enabled us to determine the efficiency with which these cells could be 
transplanted into irradiated and unirradiated recipient mice. As shown in Table III, 
exp.  1, spleen cells prepared from leukemic SIM.R  mice, i.e.,  from mice who had 
received  SFFV  +  preleukemic  cells,  proliferated  effectively in  irradiated  syngeneic 
SIM.R  but  not  in  irradiated  allogeneic BDF1  recipients.  This  indicates  that  these 
leukemic spleen cells continue to express hemopoietic histocompatibility (Hh) antigens 
but,  unlike  their  preleukemic  predecessors,  are  no  longer  rejected  by  syngeneic 
recipients.  This  observed  alteration  of transplantability  may  be  an  expression  of 
additional changes in cell surface antigen(s) which are relevant to the evolution of the 
SFFV-induced leukemia. 
Donor cells (2  X  106) were also infused into lethally irradiated SIM.R mice who 
had  been  pretreated  with  silica.  Under  these  conditions,  any  SFFV  +  leukemic or 
preleukemic cells which might have otherwise been rejected should now proliferate 
and  contribute  to  the  overall  level  of  isotope  incorporation  and  spleen  colony 
formation. However, there was no such increase observed (Table III, exp.  1). 
Finally, we inoculated SFFV  + leukemic spleen cells into infant SIM.R and alloge- 
neic BDF1 mice to determine the genotype of the developing tumors in unirradiated 
mice. Mice <21 d of age are able to temporarily accept foreign hemopoietic cell grafts 
and  a  SIM.R  tumor  will  grow  transiently  in  infant  BDF1  recipients.  Since  the 
cellularities of the tumor-filled infant SIM.R and BDF1 donor spleens were vii'tually 
identical, it is significant that intravenous injection of l0  s nucleated cells from these 
enlarged leukemic spleens resulted in >100 colonies per SIM.R secondary recipient, 
but -~ 10 colonies per BDF1 secondary recipient (Table III, exp. 2). This indicates that 
the cells harvested from BDF1 recipients did not proliferate extensively (i.e., grow as 
tumor  colonies  [TCFU])  in  allogeneic  adult  BDF1  secondary recipients  and  were 
therefore SIM.R in origin. 
Discussion 
The studies  presented  in  this  paper show conclusively that  replication defective 
Friend SFFV particles purified free from standard MuLV helper are able to persist- 
ently infect hemopoietic target cells of susceptible adult  Swiss  mice and  induce an 
erythroleukemia in the absence of overt virus replication. It has not been determined 
if the persistently infected cells or their differentiating progeny or both permit the 
expression of SFFV-induced malignant transformation. However, Friend disease was 
observed in SFFV + mice as a  poorly differentiating erythroblastic leukemia. Tumor 
cells are intimately associated with a  rescuable SFFV genome and are incapable of 
protecting lethally irradiated mice from radiation death. With the possible exception 
of the  cytoplasmic expression  of the gag  gene  product  plS,  other  viral  structural 
proteins have not been detected in SFFV + leukemic cells using indirect immunoflu- 
nrescence techniques and antigen specific heterologous antisera. Further, we have not 
been able to reveal (using complement-mediated cytotoxicity) the presence of SFFV- 
induced  antigen(s)  on  the  membrane  of transplantable  tumor  cells  using  a  wide 
variety of murine antisera directed against  syngeneic hemopoietic cells transformed 
by FV  (13, 32). Future experiments must rely upon the availability of sera directed ROBERT J.  ECKNER  AND  KRISTINE  L.  HETTRICK  353 
against SFFV  + hemopoietic and fibroblastic nor~producer cells. 
The investigation into the status of the persisting SFFV provirus was influenced by 
our belief that stable integration of SFFV into a renewing hemopoietic cell population 
(i.e., a stem cell) would result in the maintenance of rescuable SFFV for an indefinite 
period. In contrast, cells committed to a particular line of differentiation might permit 
the expression of a  stable  SFFV-host  cell association  but  would  by virtue of their 
limited life span necessitate the sequential elimination of SFFV from the hemopoietic 
system. Although we did observe a  time-related reduction in SFFV rescued in vivo, 
rescuable SFFV continued to persist in spleen tissue and was detected in the fluids of 
mixed cultures containing spleen cells and NIH/LLV fibroblasts (Fig.  1). Spleen cell 
preparations were not fractionated before addition to NIH/LLV cells and we therefore 
cannot  correlate  the  presence  of rescuable  SFFV  with  any  one  specific  class  of 
functionally or morphologically definable cell. It can be concluded, however, that the 
target cells for SFFV persistence are either very long-lived or have the potential for 
self-renewal because SFFV is replication defective and unable to persist via chronic 
or slow infections. Any amplification of SFFV presence in this model system must be 
due to hemopoietic cell proliferation. We shall pursue this matter further by coupling 
cell separation techniques with SFFV antigen detection assay systems. 
We do not know why SFFV could not be rescued in vivo beginning ~30 d  after 
inoculation into adult  Swiss  mice.  SFFV  + mice may have mobilized both humoral 
and cellular immune mechanisms which were protective against  infection by exoge- 
nous MuLV helpers. We have not been able to detect virus neutralizing antibodies in 
SFFV  ÷ preleukemic mice, but this does not  preclude the possibility of rapid devel- 
opment  of humoral  immunity  to  MuLV  infection.  It  has  been  shown  that  the 
induction  of FV  cytotoxic  antibodies  may  be  a  contributing  mechanism  in  the 
development of dormant  FV infection (33, 34)  and  in  the regression of FV disease 
(35).  An  important alternative explanation is based upon our previous observation 
that  SFFV  may  be  classified  as  a  DI  particle  (9).  DI  function(s)  alone  may  be 
responsible for the difficulties encountered in rescuing SFFV from spleens in vivo and 
in vitro. 
We feel confident that the interval between original SFFV inoculation and onset of 
Friend disease (= 100 d) can be considered a preleukemic period. Other investigators 
have identified virus-induced alterations in splenic T  and B cells (36), host immune 
functions  (37-39),  and  in  the expression of mouse histocompatibility antigens  (27, 
40-42)  shortly after FV infection and these events may certainly be involved in the 
development of Friend leukemia. The present study was not designed to investigate 
such  events, however, since we did  not  know if Friend leukemia would  ultimately 
evolve in mice inoculated with SFFV. The only documented abnormality in SFFV  + 
preleukemic mice was  an  increased number of immature smudged  cells present  in 
peripheral blood smear preparations  beginning  -~60 d  after SFFV inoculation and 
slightly elevated peripheral leukocyte counts (range of 12-20,000/mm3). At the time 
of hemisplenectomy,  SFFV  +  mice  were  shown  to  contain  spleen  cells  capable  of 
responding normally to both T  and B cell mitogens (data not shown). 
We  have  speculated  that  the  inability  of  SFFV  +  preleukemic  spleen  cells  to 
proliferate in lethally irradiated syngeneic recipient mice is due to the expression of 
SFFV-associated antigen(s) or to the altered expression of host Hh antigens. Gillis et 
al.  (43)  have recently shown  that  SFFV-encoded antigen(s)  may be present  on the 354  PERSISTENT  SPLEEN FOCUS-FORMING VIRUS INFECTION IN MICE 
surface  of SFFV-infected  fibroblastic  and  erythroleukemic cells.  However,  SFFV- 
induced leukemic cells were not a  target of syngeneic rejection in our study (Tables 
I  and III) and it is therefore likely that the antigen(s)  revealed by Gillis et al. using 
lymphocyte-mediated cytolysis assays is not involved in the phenomenon described 
here. There is also evidence for an H-2/viral protein complex on the surface of FV- 
induced tumor cells which may be responsible for an "altered self" molecule and H- 
2 restriction of cytotoxic T  cell activity in the Friend system (44,  45). The ability to 
abrogate syngeneic rejection of SFFV  + preleukemic cells via silica pretreatment of 
recipient mice strongly suggests that this natural resistance is mediated by immuno- 
genetically specific host antigraft reaction whose effector cells are relatively insensitive 
to radiation, are marrow-dependent, and  are highly sensitive to elimination by the 
bone-seeking isotope S9Sr (31).  The work of Rossi et al.  (27,  28)  and Kiessling et al. 
(46),  as  well  as  studies  concerning  the  role  of macrophages  in  regression  of FV 
leukemia  (47-49)  and our previous studies concerning Fv-2 associated resistance to 
FV (50)  have all implicated this effector cell system in surveillance over leukemoge- 
nesis. 
Finally, culture systems have been established by several groups (26,  51-53) in an 
attempt to study hemopoietic microenvironments in vitro. Addition of MuLV to these 
cultures may facilitate the study of preleukemia. However, since some of these cultures 
may  harbor  leukemic  cells  (54),  and  others  are  deficient  in  the  maintenance  of 
erythroblastic differentiation (26) we feel that SFFV  + preleukemic mice may provide 
a  model for studying the leukemia-inducing potential of hemopoietic microenviron- 
ments in vivo in the absence of virus replication. 
Summary 
A  latent  form of persistent infection can be established  in susceptible adult  mice 
inoculated with a preparation of defective Friend spleen focus-forming virus (SFFV) 
purified free from standard leukemia-inducing helper virus (LLV-F). SFFV persist- 
ence was initially observed using an in vivo rescue technique in which SFFV could be 
directly rescued to form splenic foci of malignant  erythropoiesis in mice. At  ~30  d 
after virus inoculation however, SFFV could not be rescued after inoculation of LLV- 
F  indicating  that  persistently  infected  (i.e.,  SFFV  +)  mice  were  either  immune  to 
exogenous helper virus or able to express SFFV-associated defective-interfering (DI) 
function(s). Persistent infection by SFFV was further documented using an in vitro 
rescue technique and ultimately resulted in the induction by SFFV of erythroleukemia 
in the absence of polycythemia or overt virus production. However, SFFV rescued by 
LLV-F from persistently infected normal and transformed hemopoietic cells was able 
to  induce  polycythemia in  adult  mice  suggesting  that  this  is  a  helper  controlled 
property of the Friend virus complex. Transplantable SFFV-induced erythroleukemic 
cells could be retrieved from persistently infected yet histologically normal mice. The 
duration of SFFV persistence in normal spleen tissue suggests that the SFFV provirus 
resides in either a long-lived or pluripotent hemopoietic cell. Further, certain changes 
occured, presumably in the membranes of persistently infected cells, which preceded 
the overt development of Friend leukemia and facilitated the definition of an SFFV 
preleukemic phase.  Cell  surface  alterations  were  revealed  using  cell  transfer tech- 
niques.  Hemopoietic cells  harboring  a  rescuable  SFFV  failed  to  proliferate when 
inoculated into lethally irradiated, syngeneic adult mice. In contrast, the transformed ROBERT J.  ECKNER  AND KRISTINE  L.  HETTRICK  355 
progeny of preleukemic cell populations and spleen cells transformed by FV complex 
(i.e., cells replicating both SFFV and LLV-F) were not rejected. This result suggests 
that  histologically normal  SFFV  +  preleukemic cells express an  antigen  recognition 
site which  is not present on overtly transformed cells and which may be a  pertinent 
surveillance target for host anti-leukemogenic reactions. 
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